Use of chemotherapy, endocrine, and signaling agents have also been shown to lead to reductions in Ki-67 further supporting its ability to predict treatment benefit and to serve as a marker for long-term outcomes in operable breast cancer (17). Here, MKI67 is linked to breast carcinoma.